Aemetis Reports Fourth Quarter and Year-End 2015 Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aemetis Reports Fourth Quarter and Year-End 2015 Results

CUPERTINO, CA--(Marketwired - Mar 24, 2016) - Aemetis, Inc. ( NASDAQ : AMTX ), an advanced renewable fuels and biochemicals company, today announced its financial results for the fourth quarter and twelve months ended December 31, 2015.

Financial Highlights for 2015

  • Revenues of $147 million in 2015, down from $208 million in 2014
  • Adjusted EBITDA of $(3) million in 2015, down from $30 million in 2014
  • $22 million of EB-5 funding released to the company from escrow during 2015

"In 2015, our financial and operational performance was affected by excess supply in ethanol markets," said Eric McAfee, Chairman and Chief Executive Officer of Aemetis. "During this past year, Aemetis significantly increased production at our biodiesel and glycerin biorefinery in India, to take advantage of deregulation and the removal of subsidies in the diesel market. The biodiesel domestic market in India continues to grow, with our expanding sales of B100 as a transportation fuel to replace diesel. In 2016, we plan to increase the profitability of our ethanol business by the adoption of patented technologies for the production of cellulosic ethanol and related products at the Keyes plant," added McAfee.

Today, Aemetis will host an earnings review call at 10:00 am Pacific (PT). For details on the call, visit: http://www.aemetis.com/investors/conference-call/

Financial Results for the Year Ended December 31, 2015

Revenues of $147 million during 2015 represent a 29% year-over-year decline from revenues of $208 million during 2014. For the year ended December 31, 2015, 56 million gallons of ethanol and 360 thousand tons of wet distillers grains were produced at our Keyes plant and sold at an average sales price of $1.74 per gallon and $80 per ton, respectively. For the year ended December 31, 2014, 60 million gallons of ethanol and 408 thousand tons of wet distillers grains were produced at our Keyes plant and sold at an average sales price of $2.54 per gallon and $92 per ton, respectively. Overall softness in the ethanol market due to a delay in the enforcement of the Renewable Fuel Standard by the EPA led us to operate the Keyes plant at 101% of nameplate capacity during 2015 compared to 109% of nameplate capacity during 2014. The lower ethanol production combined with the decrease in the average sales price per gallon of ethanol sold resulted in lower sales from our North America segment.

Our India subsidiary produced 19,523 metric tons of biodiesel and 4,653 metric tons of refined glycerin, resulting in 2015 revenue of $17 million, representing growth of 41% year-over-year from 2014. Significantly, biodiesel revenues from domestic India customers during 2015 were $14.1 million, a 265% increase from revenues of $3.86 million during 2014, with major milestones achieved in August 2015 from the approval of direct bulk biodiesel sales and in October 2015 from the removal of the tax on feedstock for biodiesel production.

Gross profit during 2015 of $4.2 million was down from gross profit of $37 million during 2014, primarily due to excess ethanol supply and the spread between ethanol and corn pricing in the market. Operating loss during 2015 was $8.6 million, down from operating income of $24 million in 2014.

Selling, general and administrative expenses were largely unchanged from $12.3 million during the year ended December 31, 2015 to $12.6 million during the same period of 2014.

Interest expense during the year ended December 31, 2015 of $17.2 million was largely unchanged from interest expense of $17.4 million during the same period of 2014, primarily due to the delay in realizing EB-5 monies from the escrow account and lower level of expense acceleration due to loss on debt extinguishment.

Net loss during 2015 of $27 million, or $1.37 per diluted share, compared to net income of $7.1 million or $0.34 per diluted share during 2014. Adjusted EBITDA for the twelve months ended December 31, 2015 was a loss of $3.1 million, compared to adjusted EBITDA of $30 million for the same period in 2014.

Financial Results for the Three Months Ended December 31, 2015

Revenues of $35.3 million in the fourth quarter of 2015 declined 15% from $41.5 million in the fourth quarter of 2014, primarily due to a decline in ethanol sales price per gallon, as well as lower wet distillers grains sales price per ton. During the fourth quarter of 2015, gross profit declined to $1.4 million from $2.5 million during the fourth quarter of 2014.

During the fourth quarter of 2015, selling, general and administrative ("SG&A") expenses decreased slightly to $2.8 million, compared to SG&A expense of $3.3 million during the fourth quarter of 2014. Interest and amortization expense increased slightly to $3.8 million in the fourth quarter of 2015, compared to $3.0 million in the fourth quarter of 2014 due to higher cost of debt payments.

The operating loss for the fourth quarter of 2015 of $6.5 million compares to $3.7 million of operating income during the same period of 2014. Adjusted EBITDA during the fourth quarter of 2015, resulting in a loss of $260 thousand, compared to a gain of $655 thousand of adjusted EBITDA for the same period in 2014.

"Subdued performance during 2015 reflects excess supply of ethanol in the North America segment where we continue to derive a majority of our revenues. We have been diligent in controlling our selling, general and administrative expenses," said Todd Waltz, Chief Financial Officer of Aemetis. "We have ongoing interest expense reductions through refinance activities currently underway, including $12.5 million in escrow to the company from the EB-5 program, that we believe will further lower the interest costs of the company," added Waltz.

Non-GAAP Financial Information

We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest expense, loss on extinguishment, income tax expense, intangible and other amortization expense, depreciation expense and share-based compensation expense.

Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results and for budgeting and planning purposes. EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements regarding funds to be received under our EB-5 loan program, our refinancing activities, increasing production at our biodiesel and glycerin biorefinery in India, expanding our business into rapidly growing markets with new technologies and products, our plans to construct and operate a liquid CO 2 unit and adopt patented technologies for the production of cellulosic ethanol and related products at our Keyes ethanol plant and further reductions in our outstanding debt. Words or phrases such as "anticipates," "may," "will," "should," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, counter-party risks, risks associated with changes to federal policy or regulation, risks associated with the conversion of the Keyes plant to the use of sorghum for ethanol production; and other risks detailed in our reports filed or to be filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemical company focused on the production of advanced fuels and chemicals through the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in Keyes, California. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality, distilled biodiesel and refined glycerin for customers in Europe and Asia. Aemetis operates a research and development laboratory at the Maryland Biotech Center, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com .

   
   
AEMETIS, INC.  
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS  
(unaudited, in thousands except per share data)  
   
    Three months ended     Year ended  
    December 31     December 31  
    2015     2014     2015     2014  
                                 
Revenues   $ 35,346     $ 41,475     $ 146,649     $ 207,683  
Cost of goods sold     33,902       39,023       142,450       170,539  
Gross profit     1,444       2,452       4,199       37,144  
                                 
Research and development expenses     117       117       447       459  
Selling, general and administrative expenses     2,805       3,332       12,361       12,595  
Operating income/(loss)     (1,478 )     (997 )     (8,609 )     24,090  
                                 
Interest rate expense     (2,523 )     (2,315 )     (10,164 )     (10,052 )
Amortization expense     (1,329 )     (677 )     (6,715 )     (6,038 )
Loss on debt extinguishment     0       0       (330 )     (1,346 )
Other income/(expense)     (79 )     249       (270 )     485  
Income/(loss) before income taxes     (6,453 )     (3,740 )     (27,132 )     7,139  
                                 
Income tax expense     0       0     $ (6 )   $ (6 )
                                 
Net income/(loss)   $ (6,453 )   $ (3,740 )   $ (27,138 )   $ 7,133  
                                 
Net Income/(loss) per common share*                                
  Basic   $ (0.33 )   $ (0.18 )   $ (1.37 )   $ 0.35  
  Diluted     (0.33 )     (0.18 )     (1.37 )     0.34  
                                 
Weighted average shares outstanding*                                
  Basic     19,598       20,630       19,823       20,371  
  Diluted     19,598       20,630       19,823       21,047  
                         
* The Earnings per share and Weighted average shares outstanding for all periods presented reflect the one-for-ten reverse split, which took effect May 15, 2014.  
   
   
   
   
AEMETIS, INC.  
CONSOLIDATED CONDENSED BALANCE SHEETS  
(unaudited, in thousands)  
   
    Year ended  
    December 31  
    2015     2014  
Assets                
Current assets:                
  Cash and cash equivalents   $ 283     $ 332  
  Accounts receivable     1,166       1,262  
  Inventories     4,804       4,491  
  Prepaid and other expenses     1,749       1,848  
Total current assets     8,002       7,933  
                 
  Property, plant and equipment, net     70,718       75,810  
  Goodwill, intangibles and other assets     4,421       5,433  
Total assets   $ 83,141     $ 89,176  
                 
Liabilities and stockholders' deficit                
Current liabilities:                
  Accounts payable   $ 10,183     $ 8,339  
  Current portion of long term debt, notes and working capital     11,947       12,746  
  Mandatorily redeemable Series B convertible preferred stock     2,742       2,641  
  Other current liabilities     4,425       3,590  
Total current liabilities     29,297       27,316  
                 
Total long term liabilities     89,138       64,832  
                 
Stockholders' deficit:                
  Series B convertible preferred stock     1       2  
  Common stock     20       21  
  Additional paid-in capital     82,115       87,080  
  Accumulated deficit     (114,251 )     (87,113 )
  Accumulated other comprehensive loss     (3,179 )     (2,962 )
Total stockholders' deficit   $ (35,294 )   $ (2,972 )
                 
Total liabilities and stockholders' deficit   $ 83,141     $ 89,176  
                 
                 
 
 
RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME/(LOSS)
(unaudited, in thousands)
 
    Three months ended December 31     Year ended December 31
   
    2015     2014     2015     2014
Net income/(loss)   $ (6,453 )   $ (3,740 )   $ (27,138 )   $ 7,133
Adjustments:                              
  Interest expense     2,523       2,315       10,164       10,052
  Amortization expense     1,329       677       6,715       6,038
  Loss on debt extinguishment     -       -       330       1,346
  Income tax expense                     6       6
  Intangibles and other amortization expense     32       31       129       126
  Loss on impairment of intangibles     1,044       0       1,044       0
  Depreciation expense     1,024       1,195       4,730       4,681
  Share-based-compensation     241       177       938       624
Total adjustments     6,193       4,395       24,056       22,873
Adjusted EBITDA   $ (260 )   $ 655     $ (3,082 )   $ 30,006
                               
                               
 
 
PRODUCTION AND PRICE PERFORMANCE
(unaudited)
 
    Three months ended   Year ended
    December 31   December 31
    2015   2014   2015   2014
Ethanol                        
Gallons Sold (in 000s)     13,187     14,463     55,787     60,197
Average Sales Price/Gallon   $ 1.74   $ 2.19   $ 1.74   $ 2.54
Wet Distiller's Grains                        
Tons Sold (in 000s)     84     98     360     408
Average Sales Price/Ton   $ 71   $ 67   $ 80   $ 92
Biodiesel                        
Metric tons sold     7,442     1,437     19,523     9,036
Average Sales Price/Metric ton   $ 707   $ 892   $ 724   $ 985
Refined Glycerin                        
Metric tons sold     693     655     4,653     2,236
Average Sales Price/Metric ton   $ 671   $ 778   $ 668   $ 933
                         

Investor Relations/Company/Media Contact: Satya Chillara (408) 213-0939 schillara@aemetis.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 173

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 50

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 74

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 21

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 43

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 44

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 35

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

UP Oncolytics Boosts Funding to Propel Brain Cancer Research

Updated Category News Views 171

UP Oncolytics Secures Significant Grant for Research Advancement UP Oncolytics, a pioneering biotechnology company specializing in neuro-oncology, is making headlines with its latest achievement in funding. This innovative company, a spin-out from a prominent research institution, has secured a matching grant to further its mission in developing oncolytic virus therapy...

Continue Reading
US Dollar Weakness Fuels Gold's Safe Haven Appeal Amid Trade Tensions

Updated Category News Views 269

US Dollar Weakness Benefits Gold Amid Trade Concerns The US dollar has been retreating against several major currencies, largely influenced by recent dovish comments from Fed Governor Waller. The anticipation of further developments in trade negotiations is another factor keeping investors on edge as they navigate these financial currents. Fed’s Influence on the Dollar...

Continue Reading
Tesla's Strategic Partnerships with Local Suppliers in China

Updated Category News Views 468

Tesla's Strategic Partnerships with Local Suppliers in China Tesla, Inc. (NASDAQ: TSLA) is taking significant steps to enhance its operational efficiency and local presence in the world's largest automotive market, China. Recently reported developments indicate that the iconic electric vehicle manufacturer has successfully established partnerships with over 400 local...

Continue Reading
Collect a Unique Piece of History: Trump Bobblehead Release

Updated Category News Views 324

Royal Bobbles Launches Limited Edition Bobblehead of President-Elect Trump Add an Iconic Piece of Presidential Inauguration History with a One-of-a-Kind President-Elect Donald J. Trump Bobblehead A Historic Collectible Honoring Strength and Patriotism Royal Bobbles, recognized as the original bobblehead maker, has made an exciting announcement. They are launching the 2025...

Continue Reading
Extant Capital's New $200 Million Investment Marks Growth Path

Updated Category News Views 219

Extant Capital Receives Significant Investment Boost Extant Capital, an alternative asset management firm, has made an exciting announcement regarding a substantial new investment. The firm has successfully secured a $200 million cornerstone investment from New Holland Capital, marking a pivotal moment in its growth journey. This strategic partnership is set to enhance...

Continue Reading